Skip to main content
Click Here For COVID-19 Studies
Home
Clinical Trials Office Register as a Researcher Log In
230 Studies Now Enrolling
 Menu
Home How It Works Resources Join RecruitMe

Search

Reset

Status

  • Currently Recruiting (34)
  • Closed (171)

Medical Condition

  • Show all (1747)
  • Addiction (18)
  • Allergy, Asthma, & Immunology (13)
  • All of Us Research Program - NIH (1)
  • Autoimmune Disorders (29)
  • Blood Disorders (33)
  • Bone & Muscle (10)
  • Cancer (564)
  • Child Development (4)
  • COVID-19 (Coronavirus) (36)
  • Critical Illness (1)
  • Diabetes (21)
  • Ear, Nose and Throat (11)
  • Endocrine & Metabolic Disease (12)
  • Eye (7)
  • Gastrointestinal and Digestive Diseases (26)
  • Hair and Skin Disorders (3)
  • Headaches (5)
  • Healthy Volunteers (185)
  • Heart Disease (130)
  • Infectious Disease (49)
  • Insomnia (2)
  • Kidney Disease (12)
  • Liver Disease (53)
  • Lung Disease (31)
  • Meniere's Disease (1)
  • (-) Neurological Disorders (165)
    • Alzheimer's Disease (39)
    • Brain Tumors (44)
    • Cerebral Palsy (2)
    • Dementia (8)
    • Huntington's Disease (3)
    • Multiple Sclerosis (8)
    • Neuromuscular (12)
    • Neuropathy (12)
    • Parkinson's Disease (3)
  • Nutrition (6)
  • Obesity (10)
  • Obstetrics & Gynecology (56)
  • Pain Management (1)
  • Pediatrics (102)
    • (-) Cancer (40)
      • Childhood Leukemia (6)
      • Pediatric Solid Tumors (12)
    • Cardiology (3)
    • Child and Adolescent Health (3)
    • Down Syndrome (1)
    • Neuromuscular (5)
  • Psychiatric Disorders (67)
  • Rehabilitation (8)
  • Stroke (7)
  • Surgery (7)
  • Transplant (47)
  • Urology (4)
  • Vascular Conditions (10)
Displaying 201 - 205 of 205

A study of children with relapsed or refractory solid tumors and large cell lymphoma using study drug, PF-02341066 for treatment

Condition: Cancer / Pediatric Solid Tumors
Investigator: Julia Glade Bender, MD
Status: Closed
The purpose of this study is to examine the effectiveness and tolerability of a study drug called PF-02341066. Additional goals of this study are to learn how the body handles the study drug as well as determine whether or not PF-02341066 is a beneficial treatment for your tumor This study is for children with a recurrent or progressive tumor or lymphoma…
Read More

A study for patients with Huntington's Disease using study drug Laquinimod

Condition: Neurological Disorders
Investigator: Karen Marder, MD, MPH
Status: Closed
This study is for patients with Huntington's Disease (HD). The purpose of this clinical study is to find out whether a drug called laquinimod at different doses is safe, and whether it is helpful for people with Huntingtons disease (HD). Laquinimod, the drug being studied in this project, has not been studied in patients with Huntingtons disease.…
Read More

Tolerability, Safety, and Activity of study drug SRX246 in Irritable Subjects With Huntington's Disease

Condition: Neurological Disorders / Huntington's Disease
Investigator: Karen Marder, MD, MPH
Status: Closed
The purpose of this research study is to find out whether a new investigational drug called SRX246, which might be useful to Huntington's Disease (HD) patients who sometimes feel irritable, angry, or even aggressive, is well tolerated and safe when it is given two times a day by mouth at doses as high as 160 mg. As part of this study, we will use a…
Read More

Study of E2027 in Subjects with Lewy Body Dementia (LBD) (DELPHIA)

Condition: Neurological Disorders / Dementia
Investigator: Lawrence Honig, MD, PhD
Status: Closed
This is a 22-week treatment, multicenter, double-blind, placebo-controlled, parallel group, Phase 2 study to evaluate the efficacy, safety, and tolerability of the study drug E2027, in participants with Dementia with Lewy Bodies (DLB) Lewy Body Dementia - LBD. The main purpose of this research study is to find if a new drug called E2027 works in people who…
Read More

Study of patients with neuropathy using study drug, ISIS TTR Rx

Condition: Neurological Disorders / Neuropathy
Investigator: Thomas Brannagan, MD
Status: Closed
The purpose of this study is to evaluate the efficacy and safety of ISIS TTR Rx given for 65 weeks in patients with Familial Amyloid Polyneuropathy (FAP). The purpose of this study is to determine if ISIS 420915 can help people with mild or moderate FAP. To be in this study you must have FAP and be able to walk without help or walk with using only one cane.
Read More

Pagination

  • Previous page ‹‹
  • Page 2
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE
COMPLIANCE
Compliance Hotline Compliance Program
RESOURCES
Terms of Use Privacy Policy ©2026 Columbia University
SCHOOLS
Vagelos College of Physicians and Surgeons Mailman School of Public Health School of Nursing College of Dental Medicine Graduate School of Arts and Science